{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T11:57:34Z","timestamp":1764071854749,"version":"3.45.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Most patients with autoimmune hepatitis respond to the standard of care of prednisolone in combination with a thiopurine, or a second line of mycophenolate mofetil or tacrolimus. This study aims to add to the reported experience of using rituximab in the small numbers of patients with autoimmune hepatitis who are refractory or intolerant to these treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A retrospective single center case series was performed on six patients who were treated with rituximab for probable or definite, biopsy-proven type 1 autoimmune hepatitis over a 9-year period. They were Caucasian, three males and three females, with an age at autoimmune hepatitis diagnosis ranging from 16 to 52 years old. Three patients had cirrhosis. All six patients had trialed prednisolone, a thiopurine, and also mycophenolate mofetil prior to the rituximab. Indications for rituximab were treatment of an autoimmune hepatitis flare and potential intolerance to the second line therapy. For patients with autoimmune hepatitis flare, rituximab improved transaminases and\/or total immunoglobulin G levels, lowered prednisolone dosage, and reduced the number or dose of disease-modifying agents. Four of the six cases required more than one dose of rituximab. Dosage intervals ranged from 1 month to 5 years. In one case, rituximab also effectively treated comorbid immune thrombocytopenia. No complications arose from rituximab treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Rituximab appears safe, and also effective in some patients with autoimmune hepatitis who have been refractory to standard of care. The dose reduction for other disease modifying agents makes rituximab an attractive option for this difficult to treat subset of patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-025-05595-3","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T11:52:49Z","timestamp":1764071569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of refractory autoimmune hepatitis with rituximab: a case series"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0845-3341","authenticated-orcid":false,"given":"Nicholas M.","family":"Batt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen D.","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey","family":"Haar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda J.","family":"Nicoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"2","key":"5595_CR1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/hep.31065","volume":"72","author":"CL Mack","year":"2020","unstructured":"Mack CL, et\u00a0al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020;72(2):671\u2013722.","journal-title":"Hepatology"},{"issue":"6","key":"5595_CR2","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/0016-5085(93)91081-R","volume":"105","author":"AJ Czaja","year":"1993","unstructured":"Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology. 1993;105(6):1824\u201332.","journal-title":"Gastroenterology"},{"issue":"10","key":"5595_CR3","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1111\/apt.15248","volume":"49","author":"AJ Nicoll","year":"2019","unstructured":"Nicoll AJ, et\u00a0al. Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels. Aliment Pharmacol Ther. 2019;49(10):1314\u201322.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"5595_CR4","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1016\/j.cgh.2017.06.001","volume":"15","author":"C Efe","year":"2017","unstructured":"Efe C, et\u00a0al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2017;15(12):1950-1956 e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"5595_CR5","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1007\/s10620-018-5011-x","volume":"63","author":"C Efe","year":"2018","unstructured":"Efe C, et\u00a0al. Tacrolimus and mycophenolate mofetil as second-line therapies for pediatric patients with autoimmune hepatitis. Dig Dis Sci. 2018;63(5):1348\u201354.","journal-title":"Dig Dis Sci"},{"issue":"11","key":"5595_CR6","doi-asserted-by":"publisher","first-page":"4979","DOI":"10.1007\/s10620-021-07378-4","volume":"67","author":"AJ Czaja","year":"2022","unstructured":"Czaja AJ. Advancing biologic therapy for refractory autoimmune hepatitis. Dig Dis Sci. 2022;67(11):4979\u20135005.","journal-title":"Dig Dis Sci"},{"key":"5595_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15970","author":"M Riveiro-Barciela","year":"2024","unstructured":"Riveiro-Barciela M, et\u00a0al. Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: results from the ColHai registry. Liver Int. 2024. https:\/\/doi.org\/10.1111\/liv.15970.","journal-title":"Liver Int"},{"issue":"8","key":"5595_CR8","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/apt.12042","volume":"36","author":"V Selvarajah","year":"2012","unstructured":"Selvarajah V, Montano-Loza AJ, Czaja AJ. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther. 2012;36(8):691\u2013707.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"5595_CR9","doi-asserted-by":"publisher","first-page":"e526","DOI":"10.1542\/peds.2011-1900","volume":"132","author":"D D\u2019Agostino","year":"2013","unstructured":"D\u2019Agostino D, Costaguta A, Alvarez F. Successful treatment of refractory autoimmune hepatitis with rituximab. Pediatrics. 2013;132(2):e526\u201330.","journal-title":"Pediatrics"},{"issue":"10","key":"5595_CR10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/qjmed\/hcz161","volume":"112","author":"GD Appanna","year":"2019","unstructured":"Appanna GD, et\u00a0al. Rituximab depletion of intrahepatic B cells to control refractory hepatic autoimmune overlap syndrome. QJM. 2019;112(10):793\u20135.","journal-title":"QJM"},{"issue":"11","key":"5595_CR11","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.4067\/S0034-98872011001100015","volume":"139","author":"EJ Carey","year":"2011","unstructured":"Carey EJ, Somaratne K, Rakela J. Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome. Rev Med Chil. 2011;139(11):1484\u20137.","journal-title":"Rev Med Chil"},{"issue":"5","key":"5595_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1478-3231.2006.01262.x","volume":"26","author":"ES Santos","year":"2006","unstructured":"Santos ES, et\u00a0al. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int. 2006;26(5):625\u20139.","journal-title":"Liver Int"},{"issue":"5","key":"5595_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1155\/2013\/512624","volume":"27","author":"KW Burak","year":"2013","unstructured":"Burak KW, et\u00a0al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol. 2013;27(5):273\u201380.","journal-title":"Can J Gastroenterol"},{"issue":"6","key":"5595_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.jhepr.2019.10.005","volume":"1","author":"NN Than","year":"2019","unstructured":"Than NN, et\u00a0al. Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: results from the International Autoimmune Hepatitis Group. JHEP Reports. 2019;1(6):437\u201345.","journal-title":"JHEP Reports"},{"issue":"5","key":"5595_CR15","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","volume":"31","author":"F Alvarez","year":"1999","unstructured":"Alvarez F, et\u00a0al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31(5):929\u201338.","journal-title":"J Hepatol"},{"issue":"4","key":"5595_CR16","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jhep.2021.12.041","volume":"76","author":"S Pape","year":"2022","unstructured":"Pape S, et\u00a0al. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. J Hepatol. 2022;76(4):841\u20139.","journal-title":"J Hepatol"},{"issue":"4","key":"5595_CR17","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/hep.1840180435","volume":"18","author":"PJ Johnson","year":"1993","unstructured":"Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993;18(4):998\u20131005.","journal-title":"Hepatology"},{"issue":"1","key":"5595_CR18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, et\u00a0al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169\u201376.","journal-title":"Hepatology"},{"issue":"6","key":"5595_CR19","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, et\u00a0al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736\u201345.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"5595_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/hep4.1148","volume":"2","author":"W Zhang","year":"2018","unstructured":"Zhang W, et\u00a0al. New scoring classification for primary biliary cholangitis-autoimmune hepatitis overlap syndrome. Hepatol Commun. 2018;2(3):245\u201353.","journal-title":"Hepatol Commun"},{"issue":"2","key":"5595_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/ncprheum0424","volume":"3","author":"RP Taylor","year":"2007","unstructured":"Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease\u2013the immune complex decoy hypothesis. Nat Clin Pract Rheumatol. 2007;3(2):86\u201395.","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"2","key":"5595_CR22","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/hep.24748","volume":"55","author":"M Tsuda","year":"2012","unstructured":"Tsuda M, et\u00a0al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology. 2012;55(2):512\u201321.","journal-title":"Hepatology"},{"key":"5595_CR23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1741-7015-11-88","volume":"11","author":"Z Rosman","year":"2013","unstructured":"Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med. 2013;11:88.","journal-title":"BMC Med"},{"issue":"9","key":"5595_CR24","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","volume":"72","author":"RF van Vollenhoven","year":"2013","unstructured":"van Vollenhoven RF, et\u00a0al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496\u2013502.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5595_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/MOH.0b013e32834da987","volume":"19","author":"O Wolach","year":"2012","unstructured":"Wolach O, Shpilberg O, Lahav M. Neutropenia after rituximab treatment: new insights on a late complication. Curr Opin Hematol. 2012;19(1):32\u20138.","journal-title":"Curr Opin Hematol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05595-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-025-05595-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05595-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T11:52:49Z","timestamp":1764071569000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05595-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5595"],"URL":"https:\/\/doi.org\/10.1186\/s13256-025-05595-3","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients gave written consent. The study conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by Eastern Health HREC (LR25\/2017).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient and patient\u2019s legal guardian for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A. Nicoll declares that she has received funding from Eisai, Ipsen, Astra Zeneca, and Roche for her research, unrelated to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"614"}}